02005 SSY GROUP
- 4.720
- -0.030-0.63%
SSY GROUP News
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
SSY GROUP To Go Ex-Dividend On May 21st, 2024 With 0.1 HKD Dividend Per Share
May 20th - $SSY GROUP(02005.HK)$ is trading ex-dividend on May 21st, 2024. Shareholders of record on May 22nd, 2024 will receive 0.1 HKD dividend per share on June 4th, 2024. The ex-dividend date
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Shisi Pharmaceutical Group (02005.HK): Compound electrolyte injection (500ml) has obtained approval from the Drug Administration to pass the consistent evaluation of the quality and efficacy of generic drugs
Gelonghui, May 13 | Shijiyao Group (02005.HK) announced that the Group's compound electrolyte injection (500ml) has obtained approval from China's State Drug Administration to pass the consistent evaluation of the quality and efficacy of generic drugs, which is the second domestic company to be approved. Compound electrolyte injections are mainly used as a supplementary source of water and electrolytes, and as an alkalizing agent. The compound electrolyte injection is compatible with blood and blood components. The same dosing device can be used to be transfused before or after a blood transfusion (that is, as a prefill), added to the blood component being transfused, or as a diluent for blood cells.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Shisi Pharmaceutical Group (02005) has obtained drug production registration approval for linezolid dry suspension (5ml: 100mg)
Shisi Pharmaceutical Group (02005) issued an announcement. The group has obtained the relevant linezolamide dry mix from the China National Drug Administration...
Shi Siyao Group (02005.HK) was increased by 1 million shares by executive director Qu Jiguang
Gelonghui, April 19丨According to the latest equity disclosure data of the Stock Exchange, on April 18, 2024, Shijiyao Group (02005.HK) obtained an increase of 1 million shares by Executive Director Qu Jiguang at an average price of HK$4.6752 per share on the market, involving approximately HK$4.6752 million. After increasing his holdings, Qu Jiguang's latest shareholding was 1,117,706,000 shares, and the shareholding ratio increased from 37.61% to 37.65%.
Shisi Pharmaceutical Group (02005.HK): Performance is in line with expectations, net profit margin increased year-on-year
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of HK$1,799 million, up 2.9% year on year (approximately 6.7% in RMB caliber); net profit to mother of HK$416 million, corresponding to zero profit per share
石四藥集團：2023 年報
Shi Siyao Group (02005.HK) obtained 800,000 shares from executive director Qu Jiguang
Gelonghui, April 18 | According to the latest equity disclosure data of the Stock Exchange, on April 17, 2024, Shijiyao Group (02005.HK) obtained executive director Qu Jiguang's holdings of 800,000 shares on the market at an average price of HK$4.763 per share, involving approximately HK$3.8104 million. After increasing his holdings, Qu Jiguang's latest shareholding was 1,116,706,000 shares, and the shareholding ratio increased from 37.58% to 37.61%.
Shisi Pharmaceutical Group (02005.HK) received 800,000 additional shares of common stock worth approximately HK$3,810,400 from China Pharmaceutical Company Limited
On April 17, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 17, China Pharmaceutical Company Limited increased its share holdings of $800,000 in $Shihsiyao Group (02005.HK) with an average price of HK$4.763 per share on April 17, worth about HK$3.8104 million. After the increase in holdings, China Pharmaceutical Company Limited's latest shareholding was 832 million shares, and the good position ratio rose from 27.98% to 28.01%. graphs
Shisi Pharmaceutical Group (2005.HK): Strong growth in high-volume infusion sales and APIs
Sales of large infusions are impressive. The target price is HK$6.48. The target price is HK$6.48, maintaining the “purchase” of Shijiyao in 1Q24 to achieve revenue of HK$1,799 billion (up 2.9% year over year. If the exchange rate is adjusted, revenue in RMB caliber
Changes in Hong Kong stocks 丨 Shijiao rose more than 4%, and profit attributable to Q1 shareholders increased 14.6% year-on-year
Gelonghui, April 17 | Shijiyao Group (2005.HK) rose more than 4% at the beginning of the session to HK$4.8 billion, with a market value of HK$14.3 billion. Shi Siyao announced its first quarter results last night. Profit attributable to unaudited shareholders increased by about 14.6% year-on-year to about HK$420 million. The company said that the Group's sales were mainly carried out in China and were denominated in RMB. The RMB depreciated by about 3.6% year on year against the Hong Kong dollar during the period, so the unaudited turnover only increased 2.9% year over year to about HK$1.8 billion. Gross profit increased by 2.3% to about HK$1.03 billion. Gross margin was about 57.3%, a slight decrease of 0.3 hundred from the same period last year
Selected announcements | China Electric Power's Q1 electricity sales increased by more than 30%; China Coal Energy's Q1 commercial coal sales fell by about 15%
Xinhua Insurance: Q1 received an 11.7% year-on-year decrease in total premium income; Meituan spent about HK$399 million to repurchase 4 million shares.
SSY Group Logs Nearly 15% Boost in Q1 Profit
SSY Group (HKG:2005) recorded a 14.6% rise in attributable profit for the first quarter of 2024 to approximately HK$416 million, from HK$363 million a year earlier, a Monday filing on the Hong Kong bo
Shijiyao Group (02005.HK): Net profit increased 14.6% to HK$416 million in the first quarter
On April 16, Gelonghui | Shijiyao Group (02005.HK) announced that the Group's sales are mainly carried out in China and are denominated in RMB. For the three months ending March 31, 2024, the RMB depreciated by about 3.6% against the Hong Kong dollar compared to the same period in 2023. As a result, in Hong Kong dollars, the Group's unaudited turnover for the three months ended 31 March 2024 increased by only 2.9% over the same period in 2023 to approximately HK$1,799 billion (same period in 2023: approximately HK$1,749 million). Unaudited gross profit increased by 2.3% to approximately HK$1,031 million (same period 2023: approximately 1
Profit attributable to shareholders of Shisi Pharmaceutical Group (02005) in the first quarter was approximately HK$416 million, up about 14.6% year over year
Shijiyao Group (02005) announced that the Group's sales are mainly carried out in China and are denominated in RMB. In the three months ending March 31, 2024, the RMB depreciated by about 3.6% against the Hong Kong dollar compared to the same period in 2023. As a result, in Hong Kong dollars, the Group's unaudited turnover for the three months ended March 31, 2024 increased by only 2.9% over the same period in 2023 to approximately HK$1,799 billion (same period in 2023: approximately HK$1,749 million).
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Analysis
Price Target
No Data
